Alteogen Secures $365 Million Licensing Deal for Subcutaneous Drug Platform

Platform Deal Expands Alteogen's Reach

Alteogen announced Wednesday it has closed an exclusive licensing agreement valued at up to $365 million with a global pharmaceutical company. The transaction centers on the Korean biotech's ALT-B4 platform, a recombinant human hyaluronidase enzyme designed to facilitate subcutaneous delivery of biologic drugs.

The licensing partner, whose identity Alteogen has not disclosed, will use ALT-B4 - known generically as berahyaluronidase alfa - to develop and commercialize subcutaneous formulations of biologic therapies. Subcutaneous administration offers patients an alternative to intravenous infusion, reducing treatment time and enabling home-based care for chronic conditions that currently require hospital visits.

The Technology Behind the Deal

ALT-B4 belongs to a class of enzymes that temporarily break down hyaluronic acid in the extracellular matrix, allowing larger volumes of biologic drugs to disperse through subcutaneous tissue. Alteogen developed the enzyme using its Hybrozyme technology, a proprietary expression system that produces recombinant human hyaluronidase with enhanced stability and reduced immunogenicity compared to animal-derived alternatives.

The platform has drawn interest from pharmaceutical companies seeking to reformulate existing intravenous biologics for subcutaneous use, a strategy that can extend product lifecycles and improve patient adherence. Alteogen has structured multiple partnerships around ALT-B4, positioning the enzyme as a modular component that partners can integrate into their own drug development pipelines.

Financial Structure and Milestones

The $365 million figure represents the maximum potential value of the agreement, according to Alteogen. The deal includes an upfront payment alongside milestone payments tied to development progress, regulatory approvals, and commercial sales. Alteogen will also receive tiered royalties on net sales of products incorporating ALT-B4.

The structure mirrors licensing frameworks common in the biotech sector, where platform technology owners monetize intellectual property through a combination of near-term cash and performance-linked payments. For Alteogen, which went public on the Korea Exchange in 2008, licensing revenue has become a significant component of its business model alongside proprietary drug development.

Asia's Growing Role in Biotech Licensing

The transaction underscores the expanding footprint of South Korean biotech firms in global pharmaceutical supply chains. Over the past five years, Korean companies have signed licensing and collaboration agreements worth billions of dollars with multinational pharma partners, driven by advances in biologics manufacturing, antibody engineering, and drug delivery platforms.

South Korea's government has backed the sector through regulatory reforms, R&D subsidies, and initiatives to streamline clinical trial approvals. The country's Contract Development and Manufacturing Organization sector has also matured, providing infrastructure that supports both domestic innovation and partnerships with foreign companies.

Alteogen's deal adds to a series of high-value transactions by Korean biotechs in 2025 and early 2026, reflecting investor confidence in the region's capacity to generate commercially viable platform technologies. The company's focus on enabling technologies rather than single-asset development has allowed it to diversify revenue streams and reduce binary risk.

What Comes Next

The licensing partner will advance subcutaneous formulations through preclinical studies, clinical trials, and regulatory filings in major markets. Alteogen retains rights to ALT-B4 for other partnerships and its own pipeline programs, maintaining flexibility to structure additional deals.

Investors will watch for milestone announcements and regulatory progress as the partner moves formulations through development. The timeline for commercialization will depend on the specific biologic drugs targeted, existing clinical data, and the regulatory pathway in each jurisdiction.

For Alteogen, the agreement validates its platform strategy and provides capital to fund internal programs while building a portfolio of royalty-bearing partnerships. The company continues to explore applications of ALT-B4 across therapeutic areas where subcutaneous delivery offers clinical or commercial advantages.